Idifarma, a Spanish contract development organization, has obtained authorization from the Spanish Agency of Medicines and Medical Devices to manufacture commercial batches of both conventional and high potency tablets.
With this authorization, the company can manufacture commercial batches of tablets with high level of specialization due to high containment requirements (cytotoxics, cytostatics, hormonals), or the need to manufacture small-sized batches.
Idifarma was previously authorized to manufacture batches for clinical trials, as well as for quality control and release of medicines for both commercial and investigational products.
General manager Luis Oquiñena said, “IDIFARMA will remain essentially a contract research laboratory specialized in the comprehensive development of medicines for our clients, but without any doubt, this new manufacturing authorization will allow us to offer an even more complete service beyond the elaboration of the registration dossier, and turns us into a long-term partner for our clients.”
Idifarma Gains High Potency Authorization
Published January 14, 2013
Related Breaking News
Related Online Exclusives